633 results about "Ocular disease" patented technology

Methods of treating patients with chronic thyroid eye disease are provided for herein, such as by administering antibodies and compositions that bind to and / or antagonize IGF-1R.

Disclosed herein are implantable intraocular drug delivery devices structured to provide targeted and / or controlled release of a drug to a desired intraocular target tissue, and methods of implanting and methods of using such devices for the treatment of ocular diseases and disorders. In certain embodiments, some, most, or essentially all of the device is made of biodegradable materials.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

The present disclosure relates to diagnosis of ocular diseases by leveraging an attention-based multimodal graphical neural network (AM-GNN) based on multimodal data that includes one or more image-text pairs. Each image of the image-text pair may depict a retinal scan of a subject that may correspond to one or more imaging modalities. A multimodal dataset may be collected from different imaging modalities by data crawling to automatically collect relevant data for the targeted diseases from identified sources. In some aspects, a concept bank, comprising concepts or terminologies associated with the targeted diseases, may be provided to the AM-GNN to generate a multimodal graph. The AM-GNN may be configured to find an association between a set of nodes including image-text pairs, a set of diseases, and the concepts using an attention mechanism. Based on the multimodal graph, an output may be generated, including a predicted disease and related concept(s).

The invention discloses an optic disk atrophy arc image segmentation method based on full supervision, and particularly relates to the technical field of medical equipment, and the method comprises the following steps: S1, multi-scale feature extraction, S2, local-global feature enhancement, S3, adaptive feature fusion, S4, gradient flow optimization, S5, mixing of a loss function, and S6, data enhancement and generalization optimization. According to the method, the long-range dependence of the optic disk and the atrophic arc is globally modeled through the PVTv2 encoder, the detail segmentation precision of the optic disk atrophic arc at the blood vessel crossing and fuzzy boundary is remarkably improved in combination with the multi-scale attention and dilated convolution of the feature enhancement module, cross-level feature fusion is realized with linear complexity based on the Mama decoder, and the accuracy of feature fusion is improved. Efficiency and structure coherence are considered; the weight is balanced by the mixed loss function, and early lesion missing detection is reduced; a data enhancement and residual module enhances the generalization ability of the model, and a high-precision and efficient quantitative analysis tool is integrally provided for early screening of blind eye diseases such as pathological myopia and glaucoma.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are also contemplated.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

The invention discloses homocysteine as a Graves eye disease biomarker and application thereof, the biomarker is homocysteine (Hcy), application of a reagent for detecting the biomarker in preparation of a product for diagnosing Graves eye diseases, and the reagent is used for detecting the level of Hcy in sample serum. By detecting the level of homocysteine (Hcy) in serum, an objective and quantitative biomarker is provided for diagnosis of Graves eye diseases (GO), the diagnosis accuracy is remarkably improved, and the defects that existing clinical activity scores are high in subjectivity and insensitive to latent patients are overcome; the Hcy level is in positive correlation with GO activity, and can be used for monitoring disease progression and treatment effect, optimizing disease management, reducing serious complications and improving life quality of patients.

A method and system for the use of multi-spectral retinal images to achieve an effective, efficient, and AI enabled automated retinal disease biomarker detection using biomarker identification, segmentation, and quantification. A plurality of digital multi-spectral images of a retina of a patient at a plurality of illumination wavelengths can be done using a multi-spectral ophthalmoscope. The images can then be registered, processed, and assessed to automatically quantifying one or more biomarker based on the location and size of the biomarker in the plurality of processed multi-spectral images.

Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g., engineered nucleic acids), engineered cells, compositions comprising the engineered nucleic acids, the recombinant viruses, engineered cells, engineered proteins, chemical agents that are capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, an engineered protein selected from the group consisting of OCT4; KLF4; SOX2; or any combination thereof, an antibody capable of activating expression of OCT4; KLF4; SOX2; or any combination thereof, and methods of treating a (e.g., ocular disease), preventing a disease (e.g., ocular disease), regulating (e.g., inducing or inducing and then stopping) cellular reprogramming, regulating tissue repair, regulating tissue regeneration, or any combination thereof).

The invention discloses a visual conversion system, method and equipment for eye disease auxiliary diagnosis and a storage medium, and solves the problems of single function, high data dependence, large computing resource demand and weak interpretability in the field of eye disease auxiliary diagnosis in the prior art. The system comprises an input processing module, a visual transformer trunk, a hybrid expert layer, a decoder head and an output generation module. According to the visual conversion system for eye disease auxiliary diagnosis, various ophthalmology imaging modes can be processed, multiple tasks can be executed, and the input processing module, the visual transformer trunk, the mixed expert layer, the decoder head and the output generation module in the system cooperate to reduce calculation requirements and maintain accuracy at the same time; the expert is dynamically selected according to the complexity of the input image, it is ensured that different inputs can obtain optimal feature processing, accuracy and efficiency are both considered, a decoder structure can be customized according to the features of different tasks, and the output precision of each task is ensured.

The invention relates to a multi-modal ophthalmic imaging system and method for imaging an eye of a patient. A multi-modality ophthalmic imaging system for acquiring an ophthalmic image of a patient's eye includes a first imaging module operable in a first imaging modality for acquiring a first ophthalmic image of a first portion of the patient's eye and one or more further imaging modules operable in a second imaging modality for acquiring a second ophthalmic image of a second portion of the patient's eye. The one or more further imaging modules are each operable in a different imaging modality. The imaging system further comprises a control module arranged to detect an anomaly in the first ophthalmic image indicative of an ocular disease, determine a region of interest in the eye of the patient based on the detected anomaly, where the region of interest is a region within the eye of the patient predicted to contain a second anomaly, and determine a region of interest in the eye of the patient based on the detected anomaly. And determining a second imaging modality for imaging the determined region of interest based on the second anomaly, and controlling the selected second imaging module to acquire a second ophthalmic image of the determined region of interest.

To provide a pharmaceutical composition comprising a novel compound which has a thyroid-stimulating hormone receptor antagonist activity and is useful for the treatment of thyroid-related diseases.SOLUTION: There is provided a pharmaceutical composition comprising a 3,4-dihydroquinolin-2(1H)-one compound represented by a formula (I) or a pharmacologically acceptable salt thereof. A pharmaceutical composition comprising the compound or the pharmacologically acceptable salt thereof has an antagonist activity against thyroid-stimulating hormone receptors and is useful as a therapeutic agent or the like for thyroid-related diseases (for example, hyperthyroidism, Graves' disease, thyroid eye disease and thyroid cancer).SELECTED DRAWING: None

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The present disclosure provides recombinant adeno-associated virus (AAV) virions with altered capsid protein, where the recombinant AAV (rAAV) virions exhibit greater ability to cross barriers between intravitreal fluid and retinal cells, and thus greater infectivity of a retinal cell compared to wild-type AAV, and where the rAAV virions comprise a heterologous nucleic acid. The present disclosure provides methods of delivering a gene product to a retinal cell in an individual.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention discloses an ophthalmology AI intelligent ward control system and method based on voice interaction. The system comprises an anti-noise voice acquisition unit, a multi-modal identity verification unit, a specialized semantic analysis unit, a medical rule engine unit, a safety protection unit, a multi-modal feedback unit and a dynamic optimization unit. Medical equipment noise is filtered out through a microphone array and an adaptive beam forming technology, and an instruction is analyzed in combination with a dialect recognition engine; executing triple identity verification, and performing forced superposition authentication on the cognitive impairment patient; calling an ophthalmology knowledge base to identify the risk keyword and generate a structured instruction; dynamically regulating and controlling the environment according to the eye disease type, and intercepting violation settlement according to a medical insurance rule; precise equipment voice control is forbidden, and when an emergency keyword is triggered, an OCT image is pushed preferentially and is directly connected with a physician; a big-character highlight interface and tactile pulse feedback are provided for the visually impaired patient, and data are synchronized to the HIS system in real time; and the dynamic optimization unit continuously updates the knowledge base and the medical insurance model. According to the invention, the instruction identification precision, the medical safety and the service suitability of the ophthalmology ward are obviously improved.

Provided herein are gene therapy methods for the treatment of diseases or disorders associated with the eye of a subject involving the use of recombinant adeno-associated viruses (rAAVs) comprising a variant AAV capsid to deliver a transgene to the eye of the subject. Also provided herein are rAAVs and compositions comprising the rAAVs that can be used in the gene therapy methods of the disclosure, and methods of making such rAAVs.

A system for diagnosing ocular diseases of a subject includes a mobile device (e.g., a smart phone, a tablet) to facilitate acquisition of imagery of the subject's eyes and a backend server to evaluate the imagery using a machine learning model to determine if the subject's eyes are health or unhealthy. The mobile device may execute an application to facilitate the acquisition of imagery for evaluation. In one aspect, the application may gradually ramp up the intensity of a flash when capturing imagery of the subject to reduce or, in some instances, mitigate delays caused by the camera adjusting its white balance. In another aspect, an external flash device may be coupled to the mobile device to provide a light source that is more powerful and more responsive than conventional flash devices.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases / disorders and rheumatic diseases / disorders.

Methods and compositions for treating ocular disease, including conditions associated with retinal degeneration, are provided.

The invention provides an anti-inflammatory and anti-vascular bidirectional trapping combined self-luminous power compound based on neutrophil nano-vesicles as well as a preparation method and application thereof, and belongs to the technical field of biological medicine manufacturing. The compound takes a neutrophil nano-vesicle as a carrier, and is also loaded with bis (2, 4, 5-trichlorosalicylic acid n-amyl ester) oxalate (CPPO) and a photosensitizer Ce6, and meanwhile, the surface of the compound is modified with ranibizumab through ketal mercaptan responded by ROS (reactive oxygen species). The compound has the characteristics of trapping anti-inflammatory factors and spontaneously targeting corneal neovascularization diseased regions, Ranibizumab is responsively released on the basis of ROS to be combined with vascular endothelial growth factors, the anti-angiogenesis function is achieved, meanwhile, chemical energy generated by CPPO under the high-oxygen condition stimulates Ce6 to generate singlet oxygen, and therefore the vascular endothelial cell tubulogenesis capacity is inhibited. The invention provides a new means for treatment of eye disease related diseases.

Provided herein is a method of delivering a pharmaceutical composition comprising an AAV vector to an ocular or periocular tissue, comprising injecting the AAV vector periocularly (e.g., periocular injection, optionally peribulbar injection). In some aspects, the method is for use in treating an ophthalmic pathology (e.g., thyroid eye disease (TED) in a subject in need thereof.

The invention discloses a group of blocking monoclonal antibodies of an SH1 homologous cluster fully human thyrotropin receptor (TSHR) (a TSH receptor, TSHR) as well as a preparation method and application of the blocking monoclonal antibodies of the SH1 homologous cluster fully human thyrotropin receptor (TSHR). The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH receptor blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; expression and fibrosis of effector cell orbital fibroblasts TSHR for inhibiting thyroid-related eye diseases are remarkably relieved, and wide application prospects are achieved in treatment of Graves' diseases and diseases such as thyroid eye diseases caused by hyperthyroidism.

Compositions for treating ocular disease are disclosed herein. In some embodiments, the composition comprises a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles. The dynamic hydrogel can also comprise an ocular therapeutic encapsulated by the dynamic hydrogel.